NCT04826003 2025-07-14Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-TreatmentHoffmann-La RochePhase 1 Completed54 enrolled